MEDVi vs Wegovy (2026): Real Costs, FDA Status & Verdict
By the Weight Loss Provider Guide editorial team — an independent comparison resource for GLP-1 telehealth providers. Re-verified monthly.
You searched “MEDVi vs Wegovy” for the same reason most people do: MEDVi advertises GLP-1 weight loss starting at $179 the first month, Wegovy still gets quoted at $1,349/month in older comparisons, and that gap is wide enough to make you wonder if something is off.
Something is off — but not in the way you might think. You’re not comparing two versions of the same product. You’re comparing two different paths to two different products.
The bottom line
- MEDVi is a cash-pay telehealth platform that mostly prescribes compounded GLP-1 medications (not FDA-approved as finished products), with compounded semaglutide injection at $179 first month / $299/month refills, or $179/month flat with 12-month upfront.
- Wegovy is FDA-approved semaglutide from Novo Nordisk. In 2026 your real-world price ranges from as low as $25/month with commercial insurance plus the Wegovy Savings Card, $149/month for the lowest-dose Wegovy pill cash-pay through NovoCare, or $249/month medication through Ro’s 12-month Wegovy subscription.
- The $1,349 retail figure is the list price almost no one actually pays.
Three things decide which path fits you: whether your insurance covers Wegovy, whether FDA-approved status is non-negotiable, and whether you want a pill or an injection.
Quick verdict: which one wins for your situation?
| If this is you | Better starting path | Why |
|---|---|---|
| You have commercial insurance that may cover Wegovy | Wegovy with insurance + savings card | Eligible patients can pay as little as $25/month — beats every cash-pay path |
| You're cash-pay, want FDA-approved Wegovy, and want help with insurance/prior auth | Wegovy via Ro | Ro carries FDA-approved GLP-1s, runs a free coverage checker, and includes an insurance concierge |
| You're cash-pay, want a bundled GLP-1 program, and accept the compounded route | MEDVi compounded program | Lowest entry price ($179 first month), one bundled price, 24/7 messaging, no membership fee on top |
| You want compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) | MEDVi compounded tirzepatide | Wegovy doesn't offer tirzepatide; MEDVi lists it starting at $279 first month — verify current pricing at checkout |
| You want FDA-approved tirzepatide (Zepbound) | Zepbound via Ro or your insurance | Wegovy is semaglutide-only; Zepbound is the FDA-approved tirzepatide product |
| You're not sure which path fits | Take our 60-second matching quiz | We'll match your insurance, dose, and preferences to the path most likely to work |
- Current MEDVi tablet and tirzepatide refill pricing (entry pricing is consistent; refill numbers vary between sources)
- MEDVi state availability for your specific state
- The exact medication price under MEDVi’s $99 + medication branded Wegovy route (the $99 membership is verified; medication price varies)
- Wegovy intro pricing expiration dates (the $199/month intro pen offer runs through June 30, 2026; the 4mg pill through August 31, 2026)
The 60-second answer: what’s really different about MEDVi vs Wegovy
Answer: MEDVi and Wegovy are different products in different regulatory categories. MEDVi is a telehealth platform that mostly prescribes compounded semaglutide and compounded tirzepatide — these are prepared by partner pharmacies and are not FDA-approved as finished products. Wegovy is FDA-approved semaglutide manufactured by Novo Nordisk. Most readers searching “MEDVi vs Wegovy” assume they’re comparing two prices for the same medication. They’re not — and that’s the most important thing on this page.
MEDVi's main program is not branded Wegovy
When you see "$179 starting price" on MEDVi, that's compounded semaglutide injection — a different regulatory category than FDA-approved Wegovy. MEDVi also offers a branded Wegovy route at $99 membership + medication cost, but the all-in cost typically lands above Ro or NovoCare.
The real cost of Wegovy depends on how you access it
The $1,349 list price almost no one pays. With commercial insurance and the savings card, eligible patients can pay as little as $25/month. NovoCare cash-pay: $149/month pill (lower doses), $349/month pens (standard). Ro 12-month subscription: $249/month medication.
The cost gap has narrowed dramatically in 2026
People still quote $179 vs $1,349. That's outdated. The actual 2026 decision for many cash-pay shoppers is between $299/month compounded and $249/month FDA-approved medication-only on Ro's 12-month plan. Small enough that your FDA preference, form preference, and insurance situation matter more than raw price.
Is MEDVi actually Wegovy?
Answer: No, not by default. MEDVi is a telehealth platform with several GLP-1 paths. Most are compounded medications that are not FDA-approved as finished products. There is also a separate branded Wegovy route at $99 membership + medication cost. The widely advertised “starting at $179” pricing is for compounded semaglutide injection — a different regulatory category than FDA-approved Wegovy.
MEDVi’s published medication menu
Verified against glp.medvi.org and secondary sources, April 28, 2026.
| MEDVi program | Month 1 | Refill / ongoing | Regulatory status |
|---|---|---|---|
| Compounded semaglutide injection | $179 | $299/mo (or $179/mo flat, 12-mo upfront) | Compounded — not FDA-approved as finished product |
| Compounded semaglutide tablets | $249 | $369/mo | Compounded — not FDA-approved as finished product |
| Compounded tirzepatide injection or tablets | $279 | $399/mo (verify at checkout) | Compounded — not FDA-approved as finished product |
| Branded Wegovy pill or injection | $99 membership + medication | $99/mo + medication cost | ✅ FDA-approved semaglutide from Novo Nordisk |
| Branded Ozempic injection | $99 membership + medication | $99/mo + medication cost | ✅ FDA-approved semaglutide from Novo Nordisk |
| Branded Zepbound injection | $99 membership + medication | $99/mo + medication cost | ✅ FDA-approved tirzepatide from Eli Lilly |
Can you actually get real Wegovy through MEDVi?
Yes — MEDVi offers branded Wegovy pill and Wegovy injection through its $99 membership + medication cost route. But for brand-name FDA-approved Wegovy specifically, the same medication is typically cheaper through:
- Your commercial insurance (eligible patients can pay as little as $25/month with the savings card)
- Ro’s 12-month Wegovy subscription ($249/month medication + Ro Body membership)
- NovoCare Pharmacy direct ($149/month for lower-dose pill, $199–$349/month for pens)
The label test — the only check that actually matters
Before you pay anything to MEDVi or any other GLP-1 provider, read the prescription on your checkout summary or confirmation email:
- ✓ If it says “Wegovy” with a Novo Nordisk NDC number, it’s branded Wegovy.
- ! If it says “compounded semaglutide,” “semaglutide injection (compounded),” or anything similar, it’s a compounded preparation. Not Wegovy. Both can be legitimate — but you should know which one you’re choosing.
The 8 questions to ask before paying any GLP-1 provider
- Is this prescription FDA-approved Wegovy, or a compounded medication? Get the answer in writing.
- What pharmacy will dispense it? Compounding pharmacy or regular retail pharmacy?
- Is the medication cost included in the price I’m seeing right now? Or is medication a separate charge?
- What does month two cost? First-month intro pricing is normal. Surprise refill jumps are not.
- Is there a membership fee on top of medication? Some providers stack a membership and a medication price.
- What’s the cancellation deadline and process? MEDVi requires at least 72 hours before your billing date via email or patient-portal chat.
- What happens if the prescriber decides I don’t qualify? MEDVi’s policy: medical disqualification triggers a full refund.
- Can I use my HSA, FSA, or insurance reimbursement?
MEDVi vs Wegovy cost in 2026: what you’ll really pay
Answer: MEDVi compounded semaglutide injection is $179 the first month and $299/month for refills (or $179/month flat with 12-month upfront). Wegovy ranges from as little as $25/month with commercial insurance plus the savings card, $149/month for the lower-dose pill cash-pay through NovoCare, $249/month medication on Ro’s 12-month subscription, or $349/month for standard pens through NovoCare. The accurate comparison depends on your insurance status, the form, and your commitment.
What MEDVi actually costs over a year
| MEDVi path | Month 1 | Months 2–12 | First-year total |
|---|---|---|---|
| Compounded semaglutide injection (month-to-month) | $179 | $299 | $3,468 |
| Compounded semaglutide injection (12-month upfront) | $179 | $179 | $2,148 |
| Compounded semaglutide tablets | $249 | $369 | $4,308 |
| Compounded tirzepatide injection or tablets | $279 | $399 (verify) | $4,668 (verify) |
What Wegovy actually costs over a year
| Wegovy path | Month 1 | Ongoing | First-year total | Notes |
|---|---|---|---|---|
| Wegovy with commercial insurance + savings card | As low as $25 | As low as $25 | ~$300 | Max savings $100/month; not for government beneficiaries |
| Wegovy pill (1.5mg or 4mg starter) via NovoCare cash-pay | $149 | $149 | $1,788 | 4mg offer through Aug 31, 2026; then $199/mo |
| Wegovy pill (9mg or 25mg maintenance) via NovoCare cash-pay | $299 | $299 | $3,588 | Cash-pay self-pay program |
| Wegovy pen via NovoCare cash-pay | $199 (intro) | $349 (standard) | $3,888 | Math: $199×2 + $349×10. Intro $199 through June 30, 2026 for new patients on lowest doses |
| Wegovy injection via Ro 12-month subscription (medication only) | $249 | $249 | $2,988 medication | Ro Body membership separate: $39 first month, then $149/mo or $74/mo annual prepay |
| Wegovy retail without insurance | $1,349 | $1,349 | $16,188 | List price; very few people pay this |
The honest cost reframe nobody else is leading with
- If your insurance covers Wegovy, you’re paying ~$25/month. Nothing in MEDVi’s lineup beats that. Skip MEDVi entirely.
- If you’re cash-pay and want the Wegovy pill specifically, the lowest dose is $149/month through NovoCare — cheaper than MEDVi’s compounded oral tablets at $249 first month / $369 refill.
- If you’re cash-pay and can commit 12 months, the gap between MEDVi compounded ($299/month refills) and Wegovy pen via Ro ($249/month medication + Ro Body membership) is narrower than the headlines suggest.
- If you want compounded tirzepatide, Wegovy doesn’t offer that at all. MEDVi is one of the few telehealth paths to it.
The MEDVi vs Wegovy cost-and-fit calculator
Answer 5 questions. Get your best path, a runner-up, and a first-year cost estimate.
Path calculator
Step 1 of 5
Do you have commercial insurance that might cover Wegovy?
If yes, Wegovy can cost as little as $25/month with the savings card.
Is the Wegovy pill the same thing as MEDVi tablets?
Answer: No. The Wegovy pill is FDA-approved oral semaglutide manufactured by Novo Nordisk. MEDVi’s compounded GLP-1 tablets are prepared by partner pharmacies and are not FDA-approved as finished products. They are not interchangeable, not the same regulatory category, and there is a notable scientific question about absorption pathways for compounded oral GLP-1 tablets that does not apply to the Wegovy pill.
FDA-approved Wegovy pill
- • Manufactured by Novo Nordisk under FDA-reviewed standards
- • Contains semaglutide plus SNAC absorption enhancer (allows peptide to cross the gut wall)
- • Wegovy 25mg tablets: 13.6% mean body-weight reduction at Week 64 vs 2.4% placebo, per Wegovy prescribing information
- • NovoCare cash-pay: $149/month lower doses, $299/month higher maintenance doses
MEDVi compounded tablets
- • Prepared by compounding pharmacies (not Novo Nordisk)
- • Not FDA-approved as finished products
- • Not individually evaluated by the FDA for safety, efficacy, or quality
- • $249 first month / $369/month refill for compounded semaglutide tablets
- • Compounded oral tirzepatide is the subject of pending litigation alleging absorption concerns (see FDA section below)
Why is MEDVi cheaper than Wegovy? The compounded difference, explained
Answer: MEDVi is cheaper because compounded GLP-1 medications skip several costs that branded Wegovy carries: the FDA approval process, brand marketing, and standardized pharmaceutical manufacturing supply chains. Compounded preparations can be lawful only when applicable 503A and 503B requirements are met. They are not FDA-approved as finished products and have not been individually evaluated by the FDA for safety, efficacy, or quality. The savings come with that regulatory tradeoff.
Why brand-name Wegovy costs what it costs
- • Novo Nordisk ran the STEP clinical trial program and SELECT cardiovascular trial that established Wegovy’s safety and efficacy
- • Every Wegovy pen and pill is manufactured under cGMP (FDA’s manufacturing standards)
- • The FDA reviewed the data and approved Wegovy for specific uses with specific labeling, dosing, and warnings
- • Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Why compounded GLP-1 is cheaper — and the tradeoffs
- • No FDA approval process for the specific compounded preparation
- • No big-budget brand marketing
- • Pharmacy preparation costs less than mass pharmaceutical manufacturing
- Tradeoff: Not individually FDA-evaluated for safety, efficacy, or quality
- Tradeoff: The FDA declared the semaglutide injection shortage resolved on February 21, 2025, changing which compounded preparations remain authorized
- Tradeoff: Compounded preparations carry no FDA-approved cardiovascular indication
What MEDVi actually does in this picture: MEDVi is a telehealth platform — it doesn’t manufacture medication. It partners with OpenLoop Health clinicians for prescribing review and with compounding pharmacies including Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding for medication. When you sign up with MEDVi, you’re contracting with the platform, but the prescribing clinician and the pharmacy are different entities.
What the FDA warning letter to MEDVi actually said (and didn’t say)
Answer: The FDA’s February 20, 2026 warning letter to MEDVi (#721455) cited misbranding violations on MEDVi’s website. The agency found language that falsely implied FDA approval of compounded products and falsely suggested MEDVi was the compounder of those products. The letter addressed marketing language, not medication safety. MEDVi was one of more than 30 telehealth companies the FDA warned in early 2026, and the FDA’s own Regulatory Procedures Manual describes warning letters as “informal and advisory.” It is not a recall, not a finding of guilt, and not a product safety advisory.
What the FDA DID cite
- The labeling problem: MEDVi’s website displayed compounded semaglutide and tirzepatide products with “MEDVi” on the label, suggesting MEDVi was the compounder when it is not. Cited as misbranding under FDCA sections 502(a) and 502(bb).
- The marketing-claim problem: Claims describing compounded products’ relationship to FDA-approved brands were found to “imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”
- The remedy: 15 working days to respond, identify actual compounders, provide labeling samples, and address misleading claims.
What the FDA did NOT cite
- The FDA did not find MEDVi’s medications were contaminated, improperly formulated, or unsafe.
- The FDA did not issue a recall.
- The FDA did not make findings about the prescribing clinicians, pharmacy partners, or patient outcomes.
- The FDA did not order MEDVi to stop operating.
Wegovy’s clinical evidence — and why we won’t transfer it to MEDVi’s compounded products
Answer: Wegovy’s clinical trial program is one of the most robust in obesity medicine. The STEP-1 trial showed average body weight loss of 14.9% at 68 weeks at the 2.4mg dose. The Wegovy 25mg tablet 64-week study showed 13.6% mean body weight reduction vs 2.4% for placebo. The SELECT trial established Wegovy’s cardiovascular benefit. Those results apply to FDA-approved Wegovy specifically — they do not transfer to compounded preparations, and we will not present them as if they do.
| Trial / finding | Applies to | Result |
|---|---|---|
| STEP-1 (NEJM, 2021) — Wegovy 2.4mg injection | FDA-approved Wegovy injection only | 14.9% average body weight reduction at 68 weeks; ~86% lost ≥5% of body weight |
| Wegovy 25mg tablet 64-week study | FDA-approved Wegovy pill only | 13.6% mean body weight reduction vs 2.4% placebo, per Wegovy prescribing information |
| SELECT trial (NEJM, 2023) | FDA-approved Wegovy injection only | Reduction of major cardiovascular events in adults with overweight/obesity and pre-existing cardiovascular disease — the basis for Wegovy's FDA-approved cardiovascular indication |
| MEDVi compounded preparations | Not transferable | No peer-reviewed published clinical trial data for specific compounded preparations dispensed through MEDVi. Self-reported outcomes are not equivalent to RCT data. |
Insurance changes everything — run this check first
Answer: If your commercial insurance covers Wegovy, the entire MEDVi vs Wegovy comparison shifts. Eligible patients can pay as little as $25/month for FDA-approved Wegovy with the manufacturer savings card. Government beneficiaries (Medicare, Medicaid, TRICARE, VA) cannot use the savings card. Check coverage before doing any cash-pay math.
How Wegovy can cost $25/month
The Wegovy Savings Offer applies to commercially insured patients with a valid Wegovy prescription:
- Pay as little as $25/month, with a maximum savings benefit of $100 per 1-month prescription (terms updated January 2, 2026)
- Eligible: commercial insurance with Wegovy coverage, or commercially insured opting to self-pay outside insurance, or uninsured
- Not eligible: Medicare, Medicaid, TRICARE, VA, or any other government health care program — even if you elect to self-pay
Ro’s free GLP-1 Insurance Coverage Checker submits your insurance info and returns a personalized coverage report. If your plan covers Wegovy with prior authorization, Ro’s insurance concierge handles that paperwork for you.
What if you’re on Medicare or Medicaid?
- Medicaid coverage varies by state. California’s Medi-Cal discontinued coverage of GLP-1 medications for weight-loss indications effective January 1, 2026. Other states are reviewing similar changes. Check your state’s program formulary.
- Medicare does not cover Wegovy purely for weight loss, but CMS now covers obesity medicines like Wegovy when FDA-approved for other medical reasons such as reducing major adverse cardiovascular events. The Medicare GLP-1 Bridge program (July 1 – December 31, 2027) offers eligible coverage with a $50 copay, but drugs coverable under Part D (including Wegovy for CV risk reduction) may not qualify for Bridge coverage. Verify which applies to your specific prescription.
- MEDVi is cash-pay only and does not bill insurance. Government beneficiaries can use HSA/FSA for MEDVi (subject to your account’s eligibility rules), but cannot get insurance-rate pricing.
When MEDVi is the right choice — and when it isn’t
Answer: MEDVi is most likely to fit cash-pay readers who want a bundled GLP-1 program at the lowest entry price, accept the compounded-medication regulatory category, and want either tirzepatide or simple month-to-month flexibility. It’s not the right choice for readers who require FDA-approved medication, want to use insurance, or specifically want the cardiovascular indication that only Wegovy carries.
MEDVi fits when:
- 1. You’re cash-pay and want the lowest entry price. $179 first month is the lowest entry into a serious GLP-1 program in this space. Even at $299 refills, the all-in monthly cost is below most cash-pay branded paths.
- 2. You want compounded tirzepatide. Wegovy doesn’t offer tirzepatide. MEDVi’s compounded tirzepatide starts at $279 first month.
- 3. You want one bundled price with no membership stack. MEDVi’s pricing is medication, prescriber review, support, and shipping in one number.
- 4. You want unlimited 24/7 messaging. Bundled into the price. Practical value for dose questions, side-effect check-ins, and prescription management.
- 5. You can plan around the cancellation rule. Cancel at least 72 hours before billing via email or patient-portal chat. Mark your calendar.
MEDVi doesn’t fit when:
- 1. You require FDA-approved medication. MEDVi’s main program doesn’t satisfy it. The branded Wegovy route costs more than Ro or NovoCare.
- 2. Your insurance covers Wegovy. $25/month beats $179–$299/month every time.
- 3. You want the cardiovascular indication. Only Wegovy is FDA-approved to reduce risk of major cardiovascular events in adults with established CVD and obesity/overweight. Compounded preparations carry no equivalent FDA-approved indication.
- 4. You’re highly sensitive to billing friction. MEDVi has documented Trustpilot and BBB complaints around the 72-hour cancellation window and the $179 → $299 month-two jump.
When Wegovy via Ro is the right choice — and when it isn’t
Answer: Wegovy via Ro is the cleanest FDA-approved GLP-1 path for most readers in 2026. Ro carries FDA-approved GLP-1 medications, runs a free insurance coverage checker, includes an insurance concierge that handles prior authorization paperwork, and partnered with Novo Nordisk on the multi-month Wegovy subscription program launched March 31, 2026. Ro Body membership is $39 first month, then $149/month or as low as $74/month with annual plan paid upfront. Skip Ro if you want compounded medication or if you prefer one all-in flat price.
Ro all-in cost scenarios
| Scenario | Monthly all-in |
|---|---|
| Ro Body annual ($74/mo) + Wegovy 12-month subscription ($249/mo medication) | $323/month |
| Ro Body monthly ($149/mo after $39 first) + Wegovy 12-month subscription ($249/mo) | $398/month |
| Ro Body annual ($74/mo) + Wegovy via insurance with savings card ($25/mo) | $99/month all-in for FDA-approved Wegovy |
Ro fits when:
- 1. You want FDA-approved Wegovy. Period.
- 2. You may have insurance coverage. Ro’s checker and concierge are best-in-class.
- 3. You can commit 12 months. The 12-month subscription is $249/mo medication vs $329/mo on 3-month.
- 4. You want a real prescriber relationship and ongoing care.
- 5. You may eventually move between FDA-approved GLP-1s. Ro carries Wegovy, Zepbound, and Foundayo.
Ro doesn’t fit when:
- 1. You want compounded medication. See our MEDVi vs Ro deep dive →
- 2. You want one all-in flat price without a separate membership line item. MEDVi’s model is one number; Ro’s is membership + medication.
- 3. You don’t have insurance and can’t justify $323–$398/month all-in. Ro at full cash-pay is more expensive than MEDVi’s compounded program.
Real MEDVi reviews: what customers consistently praise and complain about
Answer: MEDVi’s Trustpilot page shows a 4.4 rating with around 13,000 customer reviews. Consistent praise centers on speed of approval, 24/7 messaging, and care-team responsiveness. Consistent complaints involve billing surprises after the introductory month, the 72-hour cancellation window, and inconsistent shipping in some markets. Customer reviews are about user experience and are not used here as evidence for medical efficacy or safety.
What MEDVi customers consistently praise
- • Speed: most patients approved within 24–48 hours, medication in 3–5 business days
- • 24/7 messaging access with the care team, included in the price
- • Provider responsiveness and long-term relationships with the same prescriber
- • Anti-nausea support (ondansetron) included at no extra cost when prescribed
What MEDVi customers consistently complain about
- • Billing surprises. The most consistent negative: "$179 first month" and then surprise at $299 month two.
- • Cancellation friction. The 72-hour rule means customers who decide late to cancel get billed for another month.
- • Inconsistent shipping in some markets.
- • Mixed customer service responsiveness during billing disputes.
Pre-payment checklist — use for any provider
- Confirmed first-month price in writing
- Confirmed refill or month-two price in writing
- Confirmed whether the prescription is FDA-approved Wegovy or compounded medication
- Confirmed the dispensing pharmacy
- Confirmed cancellation deadline and process (72-hour rules at MEDVi)
- Confirmed refund policy if the prescriber declines to prescribe
- Confirmed HSA/FSA eligibility if relevant
- Set a calendar reminder for your renewal date
Side effects, safety, and what your prescriber needs to know
Answer: Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies, contraindications for personal/family history of medullary thyroid carcinoma (MTC) or MEN2, and warnings for pancreatitis, gallbladder disease, kidney injury, retinopathy, hypersensitivity, and effects with anesthesia. Common GI side effects include nausea, vomiting, diarrhea, and constipation. Any GLP-1 path requires medical screening — these are real medications with real risks, regardless of which path you choose.
Wegovy FDA Boxed Warning
Possible thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). In rodent studies, semaglutide caused thyroid tumors. It is not known whether Wegovy causes MTC in humans. Wegovy is contraindicated in patients with personal or family history of MTC, or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Other significant Wegovy warnings (per FDA-approved label)
- •Acute pancreatitis (stop Wegovy if suspected; do not restart if confirmed)
- •Acute gallbladder disease, including cholelithiasis and cholecystitis
- •Hypoglycemia, particularly when used with insulin or insulin secretagogues
- •Acute kidney injury (especially with severe GI side effects causing dehydration)
- •Hypersensitivity reactions
- •Diabetic retinopathy complications in patients with type 2 diabetes
- •Heart rate increase
- •Pulmonary aspiration during general anesthesia or deep sedation (Wegovy delays gastric emptying)
Most common Wegovy side effects (≥5%)
From the FDA-approved Wegovy label. Applies to Wegovy specifically.
What this means for compounded GLP-1 medications
Compounded semaglutide preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Specific considerations:
- Dose accuracy: Compounded preparations may have batch-to-batch variation in concentration. Verify dosing with your prescriber.
- Salt forms: The FDA has cautioned against compounded preparations using non-FDA-approved salt forms such as semaglutide sodium or semaglutide acetate. Ask whether the preparation uses semaglutide base.
- Inactive ingredients: Different compounding pharmacies use different bases and stabilizers. Ask if you have known sensitivities.
- Adverse event reporting: Report side effects to your prescriber and to the FDA’s MedWatch system.
Who should not start any GLP-1 without specialist input
- Personal or family history of medullary thyroid carcinoma or MEN2 (contraindicated)
- Severe GI conditions including gastroparesis
- Active pancreatitis or history of pancreatitis
- Active or recent gallbladder disease
- Severe kidney disease
- Pregnant or planning pregnancy (Wegovy label says discontinue at least 2 months before planned conception)
Talk to your prescriber. Telehealth screening is real screening — but it’s not a substitute for a clinician who knows your full history.
Edge cases: state availability, switching paths, what happens when you stop
Answer: MEDVi’s terms direct users to contact customer service for the current state list. Wegovy is available everywhere via NovoCare and most telehealth partners. Switching between MEDVi and Wegovy in either direction requires prescriber coordination on dose matching and timing. Most patients who stop GLP-1 medication regain a significant portion of lost weight. Build a long-term plan before you start.
State availability
MEDVi is available in most states; verify your specific state at checkout before paying (MEDVi's terms direct users to customer service for the current list). Wegovy via Ro is available in most U.S. states. Wegovy via NovoCare is available nationwide. Wegovy via your local pharmacy with insurance is available in all 50 states.
Switching from MEDVi to Wegovy
Common reason: you started cash-pay on MEDVi, your insurance now covers Wegovy. Requires prescriber coordination — your Ro or insurance prescriber will evaluate your current dose and prescribe Wegovy at an appropriate matching dose. Time the switch with the end of a MEDVi refill cycle so you don't waste medication. Cancel MEDVi at least 72 hours before your next billing date.
Stopping the medication: the part nobody talks about
In the STEP 1 extension trial, participants regained about two-thirds of prior weight loss one year after stopping once-weekly semaglutide 2.4mg plus lifestyle intervention. This is the medication's mechanism — appetite regulation. When the medication stops, appetite regulation returns to baseline. Most patients need long-term, possibly indefinite treatment to maintain weight loss. Ask your prescriber about maintenance before you start. This is one of the strongest cases for FDA-approved Wegovy through insurance if available — $25/month indefinitely beats almost everything.
The verdict: how to actually decide
The one question that decides almost everything: “Does my insurance cover Wegovy?” Find out before you do anything else. It’s free, it’s fast, and it’s the question that changes the math more than any other.
| Your situation | Best path | Take this step |
|---|---|---|
| Have commercial insurance with Wegovy coverage | Wegovy via insurance + savings card | Check Wegovy coverage on Ro (free) |
| Cash-pay, want FDA-approved, can commit 12 months | Wegovy via Ro 12-month subscription | Start Wegovy eligibility check on Ro |
| Cash-pay, want FDA-approved Wegovy pill (lower dose) | NovoCare cash-pay $149/month | Visit NovoCare directly (no affiliate) |
| Cash-pay, want a bundled compounded program at lowest price | MEDVi compounded semaglutide | See MEDVi current pricing |
| Want compounded tirzepatide (not available as Wegovy) | MEDVi compounded tirzepatide | See MEDVi tirzepatide options (verify pricing at checkout) |
| Want FDA-approved tirzepatide | Zepbound via Ro or your insurance | See Zepbound options on Ro |
| On Medicare/Medicaid | Check state Medicaid + Medicare CV indication | Check your state Medicaid formulary |
| Still not sure where you fit | Take the matching quiz | Take our 60-second GLP-1 path quiz |
MEDVi vs Wegovy: frequently asked questions
Is MEDVi the same as Wegovy?
No. Wegovy is FDA-approved semaglutide manufactured by Novo Nordisk. MEDVi is a telehealth platform that mostly prescribes compounded GLP-1 medications prepared by partner pharmacies — these are not FDA-approved as finished products. MEDVi also offers a separate branded Wegovy route at $99 membership + medication cost, but the all-in cost on that route is typically higher than going through Ro or NovoCare.
Is MEDVi cheaper than Wegovy?
Sometimes, but the gap is smaller than headlines suggest. MEDVi's compounded semaglutide injection is $179 first month and $299/month for refills. FDA-approved Wegovy ranges from $25/month with commercial insurance and the savings card, to $149/month for the lowest-dose Wegovy pill cash-pay through NovoCare, to $349/month for standard pens. With commercial insurance, Wegovy beats MEDVi. Without insurance and on a 12-month commitment, the medication-only gap is about $50/month — Ro Body membership stacks on top.
Is MEDVi FDA approved?
MEDVi is a telehealth platform — platforms aren't FDA-approved or unapproved, medications are. The compounded GLP-1 medications MEDVi mostly prescribes are not FDA-approved as finished products. Compounded preparations can be lawful when applicable Sections 503A and 503B requirements are met, but they have not been individually evaluated by the FDA for safety, efficacy, or quality.
What did the FDA warning letter to MEDVi say?
The FDA's February 20, 2026 warning letter (#721455) cited MEDVi for misbranding violations on its website — specifically, language that falsely implied FDA approval of compounded products and falsely suggested MEDVi was the compounder of those products. The letter addressed marketing language, not medication safety. MEDVi was one of more than 30 telehealth companies warned in a 2026 enforcement wave. It is not a recall or a finding of guilt.
Can I get real Wegovy through MEDVi?
Yes — MEDVi offers branded Wegovy and Ozempic through a $99 membership + medication cost model. However, the all-in medication price on this route typically lands above what you'd pay through Ro's Wegovy subscription, NovoCare direct, or your insurance. If you want FDA-approved Wegovy specifically, those alternatives are usually cheaper.
Does MEDVi take insurance?
No. MEDVi is cash-pay only and does not bill insurance. You may be able to use HSA/FSA funds for MEDVi (subject to your account's specific eligibility rules), but MEDVi does not handle prior authorization or insurance billing.
Is Wegovy effective for weight loss?
In the STEP-1 clinical trial, adults taking weekly Wegovy 2.4mg lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. Roughly 86% of participants lost at least 5% of body weight. The Wegovy 25mg tablet at 64 weeks showed 13.6% body weight reduction vs 2.4% placebo, per Wegovy prescribing information.
Does MEDVi work as well as Wegovy?
Wegovy has peer-reviewed clinical trial data backing the FDA-approved product specifically. Equivalent peer-reviewed data does not exist for MEDVi's compounded preparations. Self-reported outcomes from MEDVi customers are generally positive but are not equivalent to randomized clinical trial data, and we do not transfer Wegovy's trial results to compounded products.
Is compounded semaglutide safe?
Compounded semaglutide can be lawful when prescribed and dispensed under applicable federal and state compounding requirements. However, compounded preparations are not individually FDA-evaluated for safety, efficacy, or quality, and the FDA has documented adverse events associated with compounded semaglutide industry-wide. The FDA has also cautioned against non-FDA-approved salt forms such as semaglutide sodium or semaglutide acetate. Verify the pharmacy and the preparation form with your prescriber.
How much does Wegovy cost without insurance in 2026?
Through NovoCare cash-pay: Wegovy pill is $149/month for 1.5mg or 4mg starter doses (4mg offer through August 31, 2026, then $199/month) and $299/month for higher maintenance doses. Wegovy pen is $199/month intro for 0.25mg/0.5mg new patients through June 30, 2026, then $349/month for standard pens. Through Ro's 12-month Wegovy subscription: medication is $249/month plus Ro Body membership.
How do I cancel MEDVi?
Email MEDVi customer service or use the patient-portal chat at least 72 hours before your next billing cycle. If you miss the deadline, the next charge processes and cancellation takes effect for the following cycle. Mark your renewal date in your calendar.
What's the cheapest way to get FDA-approved Wegovy?
If you have commercial insurance plus the Wegovy Savings Card, you can pay as little as $25/month (max $100/month savings; not available to Medicare, Medicaid, TRICARE, or VA beneficiaries). If you're cash-pay, the cheapest path depends on form and dose: Wegovy pill at lower doses is $149/month through NovoCare, and Wegovy pen on Ro's 12-month subscription is $249/month medication plus Ro Body membership.
Is Ro better than MEDVi for Wegovy?
For FDA-approved Wegovy specifically, yes — Ro is the cleaner path. Ro carries FDA-approved GLP-1 medications, runs a free insurance coverage checker, includes an insurance concierge, and partnered with Novo Nordisk on the multi-month Wegovy subscription program. MEDVi is the better fit if you want a bundled compounded GLP-1 program rather than FDA-approved Wegovy.
Is the Wegovy pill the same as MEDVi tablets?
No. The Wegovy pill is FDA-approved oral semaglutide manufactured by Novo Nordisk, containing a specialized absorption enhancer (SNAC) that allows the peptide to cross the gut wall. MEDVi's compounded GLP-1 tablets are prepared by partner pharmacies and are not FDA-approved as finished products. They are not the same regulatory category and not interchangeable. The Wegovy pill at the lowest doses ($149/month) is also cheaper than MEDVi's compounded oral tablets ($249 first month, $369 refill).
Final next step
If we did our job, you now know the three things that decide which path fits you: your insurance situation, whether FDA-approved status is non-negotiable, and whether you want a pill or an injection.
- If you have insurance that covers Wegovy — use it. Check coverage on Ro (free, ~2 min).
- If you’re cash-pay and want FDA-approved Wegovy — Ro is the cleanest path. 12-month subscription at $249/month medication, Ro Body as low as $74/month annual.
- If you’re cash-pay, want compounded, and accept the regulatory category — MEDVi is a real option. $179 first month, bundled price, no membership fee on top.
- If you want compounded tirzepatide specifically — MEDVi is one of the few telehealth paths. Verify current pricing at checkout.
Still not sure? Take our free 60-second GLP-1 path quiz →
How we built this comparison
This page synthesizes verified pricing from MEDVi.org, NovoCare.com, Wegovy.com, and Ro.co; regulatory facts from the FDA warning letter database, FDA press announcements, Novo Nordisk press releases, and FDCA Sections 503A and 503B; clinical evidence from peer-reviewed STEP and SELECT trials and Wegovy’s FDA-approved prescribing information; and customer experience patterns from public Trustpilot, BBB, ConsumerAffairs, and Reddit reviews.
What we actually verified — the transparency table
| Claim | Verified? |
|---|---|
| MEDVi compounded semaglutide injection: $179 first / $299 refill | ✅ Yes — medvi.org pricing pages, April 28, 2026 |
| MEDVi semaglutide at $179/mo with 12-month upfront | ✅ Yes — U.S. News MEDVi review |
| MEDVi 72-hour cancellation rule via email or portal chat | ✅ Yes — MEDVi cancellation/refund policy |
| MEDVi medical-disqualification full refund | ✅ Yes — MEDVi cancellation/refund policy |
| MEDVi $99 + medication for branded Wegovy/Ozempic/Zepbound | ✅ Yes — medvi.org pricing pages |
| MEDVi pharmacy partners: Triad Rx, RedRock Pharmacy, Beaker Pharmacy | ✅ Yes — medvi.org disclosures |
| FDA Warning Letter #721455 (February 20, 2026) | ✅ Yes — FDA Warning Letter Database |
| 30 telehealth companies warned in March 2026 | ✅ Yes — FDA press announcement |
| Wegovy injection list price: $1,349.02/month | ✅ Yes — NovoCare.com |
| Wegovy savings card: as low as $25/month, max $100/month savings | ✅ Yes — NovoCare.com (terms updated Jan 2, 2026) |
| Wegovy pill cash-pay: $149/month (1.5mg, 4mg starter) | ✅ Yes — NovoCare price guide |
| Wegovy pen via Ro 12-month subscription: $249/month medication | ✅ Yes — Novo Nordisk press release, March 31, 2026 |
| STEP-1 trial: 14.9% average body weight loss at 68 weeks | ✅ Yes — NEJM, 2021 |
| Wegovy 25mg tablet: 13.6% body weight reduction at Week 64 | ✅ Yes — Wegovy prescribing information |
| STEP 1 extension: ~two-thirds weight regain one year after stopping | ✅ Yes — STEP 1 extension publication |
| Semaglutide injection shortage resolved Feb 21, 2025 | ✅ Yes — FDA Drug Shortage Database |
| Wegovy CV indication for adults with established CVD + obesity | ✅ Yes — Wegovy FDA-approved label |
| California Medi-Cal stopped GLP-1 weight-loss coverage Jan 1, 2026 | ✅ Yes — California Medical Association |
What we did not claim
- We did not claim compounded medications are FDA-approved
- We did not transfer Wegovy clinical trial results to MEDVi’s compounded products
- We did not use customer reviews as medical evidence
- We did not invent author credentials or fabricate a medical reviewer